Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Amphastar Pharmaceuticals, Inc. - Common Stock (NQ:AMPH)

27.16 +0.16 (+0.59%)
Streaming Delayed Price Updated: 3:26 PM EDT, Sep 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amphastar Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
AMPHASTAR PHARMACEUTICALS INC (NASDAQ:AMPH) – A Potentially Undervalued Stock Worth Watching
AMPH ASTAR PHARMACEUTICALS INC (NASDAQ:AMPH) offers strong profitability and an undervalued stock price, making it a candidate for value investors. Check the full analysis for details. 
Via Chartmill
This Target Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday
 
Via Benzinga
Amphastar Pharmaceuticals to Present at the 2025 Bank of America Health Care Conference
Via ACCESS Newswire
Amphastar Pharmaceuticals (NASDAQ:AMPH) Misses Q1 Sales Targets
Pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) fell short of the market’s revenue expectations in Q1 CY2025, with sales flat year on year at $170.5 million. Its non-GAAP profit of $0.74... 
Via StockStory
Earnings Scheduled For May 7, 2025
 
Via Benzinga
Earnings Outlook For Amphastar Pharma
 
Via Benzinga
Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full Year Ended December 31, 2024
Via ACCESS Newswire
Earnings Scheduled For February 27, 2025
 
Via Benzinga
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2025
Via ACCESS Newswire
Amphastar Pharmaceuticals Inc (NASDAQ:AMPH): A Closer Look at Dividend Potential
Amphastar Pharmaceuticals Inc (NASDAQ:AMPH): A Closer Look at Dividend Potential 
Via Chartmill
Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 7th, 2025
Via ACCESS Newswire
2 Healthcare Stocks on Our Watchlist and 1 to Be Wary Of
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory... 
Via StockStory
Topics Stocks
Generic Pharmaceuticals Stocks Q4 Teardown: Viatris (NASDAQ:VTRS) Vs The Rest
Let’s dig into the relative performance of Viatris (NASDAQ:VTRS) and its peers as we unravel the now-completed Q4 generic pharmaceuticals earnings season. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) is an undervalued gem with solid fundamentals.
Uncover the potential of AMPHASTAR PHARMACEUTICALS IN, an undervalued stock. NASDAQ:AMPH maintains a strong financial position and offers an appealing valuation. 
Via Chartmill
2 Safe-and-Steady Stocks with Solid Fundamentals and 1 to Think Twice About
Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets. 
Via StockStory
2 Reasons to Like AMPH and 1 to Stay Skeptical
What a brutal six months it’s been for Amphastar Pharmaceuticals. The stock has dropped 50.3% and now trades at $24.50, rattling many shareholders. This was partly due to its softer quarterly results... 
Via StockStory
Topics Supply Chain
Amphastar Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference
Via ACCESS Newswire
International Medication Systems, Ltd. Receives FDA's Drug Shortage Assistance Award
Via ACCESS Newswire
AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH), an undervalued stock with good fundamentals.
Take a closer look at AMPHASTAR PHARMACEUTICALS IN , a remarkable value stock. NASDAQ:AMPH excels in fundamentals and maintains a very reasonable valuation. 
Via Chartmill
Q4 Earnings Highs And Lows: Amphastar Pharmaceuticals (NASDAQ:AMPH) Vs The Rest Of The Generic Pharmaceuticals Stocks
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at generic pharmaceuticals stocks, starting... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
Amphastar Pharmaceuticals to Present at the Barclays 27th Annual Global Healthcare Conference
Via ACCESS Newswire
Generic Pharmaceuticals Stocks Q4 In Review: Amneal (NASDAQ:AMRX) Vs Peers
Wrapping up Q4 earnings, we look at the numbers and key takeaways for the generic pharmaceuticals stocks, including Amneal (NASDAQ:AMRX) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
Specialty Pharma Amphastar Stock Falls On Lower Than Expected Q4 Earnings, Analyst Sees Competitive Headwinds
Amphastar's Q4 sales grew 20% to $186.5M, missing estimates. Primatene MIST surpassed $100M in annual sales, while Baqsimi saw strong growth. 
Via Benzinga
Amphastar: Earnings Miss, Margins Drop
Amphastar Pharmaceuticals posted modest earnings growth but fell short of market expectations in its latest quarterly results. 
Via The Motley Fool
Topics Earnings
Amphastar Pharmaceuticals (NASDAQ:AMPH) Misses Q4 Sales Targets, Stock Drops 12.1%
Pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) missed Wall Street’s revenue expectations in Q4 CY2024 as sales rose 4.7% year on year to $186.5 million. Its non-GAAP profit of $0.92 per... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
Earnings To Watch: Amphastar Pharmaceuticals (AMPH) Reports Q4 Results Tomorrow
Pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) will be reporting earnings tomorrow after market hours. Here’s what to expect. 
Via StockStory
Top 2 Health Care Stocks That May Rocket Higher This Month
 
Via Benzinga
Q3 Earnings Outperformers: Viatris (NASDAQ:VTRS) And The Rest Of The Generic Pharmaceuticals Stocks
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how generic pharmaceuticals stocks fared in Q3, starting with... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on February 27, 2025
Via ACCESS Newswire
Generic Pharmaceuticals Stocks Q3 Teardown: Amneal (NASDAQ:AMRX) Vs The Rest
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how generic pharmaceuticals stocks fared in Q3, starting with... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.